{"classes":[{"categories":[{"measurements":[{"comment":"not estimable since few responders had DP by the time the study was terminated","groupId":"OG000","lowerLimit":"7.2","upperLimit":"NA","value":"10.3"},{"comment":"not estimable since no responder had DP by the time the study was terminated","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Duration of response (for responders only) was defined as the time from earliest date of documented response (PR or better) to the earliest date of disease progression (DP) as determined by the investigator per IMWG Uniform Response criteria or death during study treatment, whichever occurred first.","dispersionType":"80% Confidence Interval","groups":[{"description":"High risk, transplant non-eligible \\[TNE\\], newly diagnosed multiple myeloma (NDMM) participants who were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \\[CrCl\\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG000","title":"Cohort A: High Risk, TNE"},{"description":"\\>= 65 years old, transplant non-eligible \\[TNE\\], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \\[CrCl\\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles.","id":"OG001","title":"Cohort B: >=65 Years Old, TNE"},{"description":"High risk, post-transplant NDMM participants were administered the following as maintenance therapy: • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle.","id":"OG002","title":"Cohort C: High Risk, Post-transplant"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Population: Participants in Cohorts A + B who had a response.","reportingStatus":"POSTED","timeFrame":"Day 1 of each cycle starting with Cycle 2 up to Cycle 17 plus one week for the end of treatment visit (Day 29 up to Week 73)","title":"Kaplan-Meier Estimates for Duration of Response (for Cohort A and B)","type":"SECONDARY","unitOfMeasure":"months"}